AFT PharmaceuticalsNZSE:AFT +0.27%96 EBITDA Margin % is 14.75% as of Mar. 2026, which is 34% above its 10-year median of 11.03. GuruFocus rates NZSE:AFT with a GF Score™ of 96/100 and a GF Value™ of NZ$4.15 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, AFT Pharmaceuticals ranks worse than 53.4% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. AFT Pharmaceuticals's EBITDA for the
six
months ended in Mar. 2026 was NZ$20.3 Mil. AFT Pharmaceuticals's Revenue for the
six
months ended in Mar. 2026 was NZ$137.7 Mil. Therefore, AFT Pharmaceuticals's EBITDA margin for the quarter that ended in Mar. 2026 was 14.75%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
AFT Pharmaceuticals EBITDA Margin % Related Terms
AFT Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for AFT Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:AFT vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AFT Pharmaceuticals (NZSE:AFT) has a EBITDA Margin % of 14.75% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AFT Pharmaceuticals and its competitors. This is 34% above median its historical median of 11.03. According to the industry distribution chart, AFT Pharmaceuticals ranks #510 out of 955 companies in the Drug Manufacturers industry, placing it in the top 53.4%.
Is AFT Pharmaceuticals' EBITDA Margin % too high?
AFT Pharmaceuticals' current EBITDA Margin % of 14.75% is 34% above median its 10-year median of 11.03. The Drug Manufacturers industry median EBITDA Margin % is 12.44. AFT Pharmaceuticals' value of 14.75% is 18.6% above this industry median. Based on the distribution chart, AFT Pharmaceuticals ranks #510 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, AFT Pharmaceuticals has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #510 out of 955 companies for EBITDA Margin %. This places AFT Pharmaceuticals in the lower half of its industry. The industry median EBITDA Margin % is 12.44. AFT Pharmaceuticals' value of 14.75% is 18.6% above this benchmark. While the company's 10-year median is 11.03 vs. the industry median of 12.44, AFT Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AFT Pharmaceuticals's current EBITDA Margin % of 14.75% is 18.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AFT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current EBITDA Margin % is 14.75%, which is 34% above median its own 10-year median of 11.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (NZSE:AFT) is currently considered Modestly Undervalued. The stock's GF Value™ is NZ$4.15, compared to a current price of NZ$3.68 — trading 11.3% below its estimated fair value. The current EBITDA Margin % is 14.75%, which is 34% above median its 10-year median of 11.03 and 18.6% above the Drug Manufacturers industry median of 12.44. AFT Pharmaceuticals' overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For AFT Pharmaceuticals (NZSE:AFT), the current EBITDA Margin % is 14.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (NZSE:AFT) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued.
The current stock price of NZ$3.68 is trading 11.3% below its estimated GF Value™ of NZ$4.15.
GuruFocus considers AFT Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NZSE:AFT:
EBITDA Margin %: 14.75% (34% above median its 10-year median of 11.03)
GF Value™: NZ$4.15 vs. price of NZ$3.68 (11.3% below fair value)
Industry Position: 18.6% above the Drug Manufacturers median (#510 of 955)
No single metric tells the full story. See the NZSE:AFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
96GF Score
Get the complete analysis for NZSE:AFT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:AFT has been successfully added to your 
